• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Applied Molecular Transport Inc.

    1/9/24 6:12:27 AM ET
    $AMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMTI alert in real time by email
    15-12G 1 amti20240108_1512g.htm FORM 15-12G amti20240108_1512g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM 15

     


     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number: 001-39306

     

    APPLIED MOLECULAR TRANSPORT INC.

    (Exact name of registrant as specified in its charter)

     

    6714 NW 16th Street, Suite B

    Gainesville, Florida 32653

    (386) 418-8060

    (Address, including zip code, and telephone number, including area code,

    of registrant’s principal executive offices)

     

    Common Stock, par value $0.0001 per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities covered by this Form)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

     

    Rule 12g-4(a)(1)

    ☒

     
      Rule 12g-4(a)(2) ☐  
     

    Rule 12h-3(b)(1)(i)

    ☒

     
     

    Rule 12h-3(b)(1)(ii)

    ☐

     
     

    Rule 15d-6

    ☐

     
      Rule 15d-22(b) ☐  

     

    Approximate number of holders of record as of the certification or notice date: 1

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Applied Molecular Transport Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

     

    APPLIED MOLECULAR TRANSPORT INC.

     

     

     

     

     

    Date: January 9, 2024

    By:

    /s/ N. Scott Fine

     

     

    Name:

    N. Scott Fine

     

     

    Title:

    Chief Executive Officer

     

     

     
    Get the next $AMTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Epiq Capital Group, Llc disposed of 8,337,518 shares (SEC Form 4)

      4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

      12/29/23 5:40:35 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vandevender Aaron returned 212,659 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

      12/28/23 5:39:57 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Smither John W

      4 - Applied Molecular Transport Inc. (0001801777) (Issuer)

      12/28/23 5:38:19 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts for oral AMT-101 in ulcerative colitis (UC) and rheumatoid arthritis (RA) anticipated in 2022, consistent with previous guidance SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. "We were pleased to recently announce positive top-line data from our FILLMORE trial in chronic pou

      5/9/22 4:01:00 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport Appoints Charlene Banard to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Charlene Banard to its Board of Directors. Ms. Banard is an accomplished biopharmaceutical executive with over 30 years of experience leading global technical operations and quality organizations within the life sciences industry. Ms. Banard will also become a member of the company's Audit Committee. "Charlene is a welcome addition to AMT's Board of Directors, bringing critical technical operations expertise and a strong strategic vision to the organization," said Tahir Mahmood, Ph.D.,

      4/6/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs

      Company continues to strengthen key functions and corporate leadership Company on track to announce top-line data from four ongoing oral AMT-101 Phase 2 trials in 2022 SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn Finkle as senior vice president, head of regulatory affairs. She becomes a member of the AMT executive leadership team, reporting to chief executive officer and co-founder of AMT, Tahir Mahmood, Ph.D. "We are thrilled to welcome Carolyn as the newest member of the executive leadership team at AMT," said Dr. Mahmood. "Car

      3/14/22 8:00:00 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Applied Molecular Transport Inc.

      15-12G - Applied Molecular Transport Inc. (0001801777) (Filer)

      1/9/24 6:12:27 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Applied Molecular Transport Inc.

      EFFECT - Applied Molecular Transport Inc. (0001801777) (Filer)

      1/3/24 12:15:07 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by Applied Molecular Transport Inc.

      POSASR - Applied Molecular Transport Inc. (0001801777) (Filer)

      1/2/24 9:15:36 AM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Applied Molecular Transport Inc. (Amendment)

      SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)

      2/14/24 4:24:03 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Applied Molecular Transport Inc. (Amendment)

      SC 13D/A - Applied Molecular Transport Inc. (0001801777) (Subject)

      1/5/24 4:18:22 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Applied Molecular Transport Inc. (Amendment)

      SC 13G/A - Applied Molecular Transport Inc. (0001801777) (Subject)

      2/9/23 4:05:59 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care